Clinical trials: Renal Transplant Recipient
Pyelonephritis Acute, Kidney Transplant Infection
Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.
Infections are a major cause of morbidity and mortality in solid organ transplant recipients. In kidney transplant recipients (KTR) urinary tract infection (UTI) represent 45-72% of all infections, and 30% of all hospitalizations…
- Trial name
- SHORTCUT (NCT05597540)
- Testing
- Short antibiotic treatment, Usual antibiotic treatment
- Where
- 9 sites in France
- Volunteers
- 470 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplantation
Cell Therapy for Immunomodulation in Kidney Transplantation
This study investigates treatment with recipient regulatory T cells and donor bone marrow together with tocilizumab for immunomodulation in living donor kidney transplant recipients.
- Trial name
- NCT03867617
- Testing
- Regulatory T cells, Tocilizumab, Bone marrow
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Thomas Wekerle
Invasive Fungal Infections, Lung Transplantation
Isavuconazole Therapeutic Drug Monitoring in Transplant Recipients
Isavuconazole is an antifungal medicine used to prevent or treat serious fungal infections in people who have received a solid organ transplant (mainly lung, and also kidney or liver) or a hematopoietic stem cell (bone marrow)…
- Conditions
- Invasive Fungal Infections, Lung Transplantation, Hematopoietic Stem Cell Transplantation (HSCT), Kidney Transplantation
- Trial name
- TRIM-1 (NCT07716878)
- Testing
- Isavuconazole
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhibin Xu
Porto-Sinusoidal Vascular Disease
Risk Factors for Portosinusoidal Vascular Disease in Kidney Transplant Recipients:
To look for the factors of exposure present prior to the onset of Porto-Sinusoidal Vascular Disease (PSVD) and which can lead to the occurrence of PSVD after renal transplantation, and therefore to consider the identification of…
- Trial name
- TRANSVAS (NCT05388409)
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Caen
Renal Transplant Rejection, Renal Transplant Failure
Heme Arginate in Transplantation Study
Organ shortage for transplant has necessitated use of kidneys from older donors, increasing the chance that the kidney will not work immediately or for as long as expected.
- Trial name
- HOT2 (NCT03646344)
- Testing
- Heme Arginate 25 MG/ML, 0.9% Sodium-chloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- University of Edinburgh
Postoperative Renal Function
Intraoperative Laser Speckle Imaging Predicts Early Renal Function After Kidney Transplantation
This observational study aims to explore the predictive value of intraoperative laser speckle contrast imaging for early postoperative renal function in kidney transplant recipients.
- Trial name
- NCT07753434
- Testing
- laser speckle contrast imaging (LSCI)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Renal-urinary Impairment, Graft Rejection
Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients
BK virus (BKV) is a ubiquitous virus that infects more than 80% of the population. In case of immunosuppression, BKV can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow…
- Conditions
- Renal-urinary Impairment, Graft Rejection, Infection Episodes
- Trial name
- BKV-Pneumo (NCT04164576)
- Testing
- Transplant patients
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplant Recipients
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
This study is specifically designed to determine whether the initiation of Myfortic 2 weeks prior to transplantation will enhance the therapeutic efficacy of Simulect induction therapy in low to moderate risk patients.
- Trial name
- NCT01336296
- Testing
- mycophenolic acid
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Cincinnati
Hyperlipidemias
Lipid Management in Renal Transplant Recipients Using Evolocumab.
Cardiovascular disease is the leading cause of mortality after renal transplantation, accounting for more than 30% of deaths. Elevated lipid levels (hyperlipidemia) are a frequent finding following transplantation and the…
- Trial name
- NCT04608474
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Brigham and Women's Hospital
Kidney Disease, Proteinuria
Angiotensin II Blockade for Chronic Allograft Nephropathy
Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive.
- Trial name
- NCT00067990
- Testing
- Losartan 100mg
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- University of Minnesota
Heart Transplantation
L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function
exercise capacities are still altered after heart transplantation partly due to peripheral endothelial dysfunction cyclosporin-induced renal dysfunction may be due to renal endothelial dysfunction and can be reversed in an animal…
- Trial name
- NCT00213915
- Testing
- 12 g of L-arginine glutamate during 6 weeks twice a day
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
End Stage Renal Disease
Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients
An observational cohort study will be conducted to non-invasively investigate central blood pressure and pulse wave velocity in children with kidney disease and controls.
- Trial name
- NCT04212143
- Testing
- there is no intervention
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's National Research Institute
Renal Transplant Patients
CNS Study of Patients Switching From Tacrolimus to Envarsus
This is a pilot study documenting the neurotoxic side effects including tremors in patients with a stable graft who are receiving Tacrolimus following kidney transplantation.
- Trial name
- NCT03270462
- Testing
- Envarsus XR
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Renal Transplantion, Kidney Transplantion
A Pilot Trial to Evaluate the Effect of Diet and Exercise in Renal Transplant Recipients on Tacrolimus
The purpose of this trial is to investigate whether a combined dietary and exercise intervention, added to standard care, reduces the expected frequency of insulin resistance in renal (kidney) transplant recipients on tacrolimus.
- Trial name
- PRIDE (NCT00492661)
- Testing
- Tacrolimus With Diet and Exercise Intervention
- Where
- 4 sites in Australia
- Volunteers
- 55 people
- Sponsor
- Janssen-Cilag Pty Ltd
Proteinuria, Transplant Glomerulopathy
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.
- Trial name
- NCT02057523
- Testing
- Acthar
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Illinois Chicago
Renal Transplant
CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients
In order to avoid renal transplant rejection, the immune system should be suppressed. After the renal transplant subjects are treated with a combination of two to four different types of immunosuppressive drugs.
- Trial name
- MMF (NCT00737659)
- Testing
- Mycophenolate mofetil (CellCept® )
- Where
- 2 sites in Israel
- Volunteers
- 138 people
- Sponsor
- Rabin Medical Center
Renal Impairment, Liver Transplantation
CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation
The primary objective of the trial is to evaluate efficacy and safety of delayed introduction (up to 30 days post-transplantation in patients without signs of acute rejection that had received an aIL-2 induction and MMF) of…
- Conditions
- Renal Impairment, Liver Transplantation, Everolimus
- Trial name
- BUILT_01 (NCT01023542)
- Testing
- delayed, low-dose CNI, BU-CNI, BU-Everolimus
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University of Regensburg
Gastrointestinal Lesions, Signs and Symptoms, Digestive
Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
The purpose of this study is to learn more about symptoms and gastrointestinal lesions associated with taking myfortic® by switching patients to a delayed release formulation that is developed to alleviate GI symptoms.
- Trial name
- NCT00652834
- Testing
- Small bowel capsule endoscopy (SBCE), myfortic
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Los Angeles
Kidney Pancreas Transplantation
CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients
This is a Phase II/III, Single-center, Prospective, Open-label, Single Arm Study of 20 Simultaneous Kidney Pancreas recipients who received a transplant at least 3 months, but no more than 5 years prior, with a history of tremors…
- Trial name
- NCT03769298
- Testing
- Envarsus XR
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplant Recipients
Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients
The purpose of this study is to find out whether Varivax is safe for use in children with kidney transplants and whether it protects children from serious infection.
- Trial name
- NCT00005009
- Testing
- Varivax®
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)